1353 related articles for article (PubMed ID: 12913770)
1. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R
J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.
Passwell JH; Harlev E; Ashkenazi S; Chu C; Miron D; Ramon R; Farzan N; Shiloach J; Bryla DA; Majadly F; Roberson R; Robbins JB; Schneerson R
Infect Immun; 2001 Mar; 69(3):1351-7. PubMed ID: 11179298
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
[TBL] [Abstract][Full Text] [Related]
5. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.
Passwell JH; Ashkenazi S; Banet-Levi Y; Ramon-Saraf R; Farzam N; Lerner-Geva L; Even-Nir H; Yerushalmi B; Chu C; Shiloach J; Robbins JB; Schneerson R;
Vaccine; 2010 Mar; 28(10):2231-2235. PubMed ID: 20056180
[TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
Oaks EV; Turbyfill KR
Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
[TBL] [Abstract][Full Text] [Related]
7. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
Riddle MS; Kaminski RW; Di Paolo C; Porter CK; Gutierrez RL; Clarkson KA; Weerts HE; Duplessis C; Castellano A; Alaimo C; Paolino K; Gormley R; Gambillara Fonck V
Clin Vaccine Immunol; 2016 Dec; 23(12):908-917. PubMed ID: 27581434
[TBL] [Abstract][Full Text] [Related]
8. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.
Cohen D; Ashkenazi S; Green MS; Gdalevich M; Robin G; Slepon R; Yavzori M; Orr N; Block C; Ashkenazi I; Shemer J; Taylor DN; Hale TL; Sadoff JC; Pavliakova D; Schneerson R; Robbins JB
Lancet; 1997 Jan; 349(9046):155-9. PubMed ID: 9111538
[TBL] [Abstract][Full Text] [Related]
9. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study.
Chisenga CC; Bosomprah S; Simuyandi M; Mwila-Kazimbaya K; Chilyabanyama ON; Laban NM; Bialik A; Asato V; Meron-Sudai S; Frankel G; Cohen D; Chilengi R
PLoS One; 2021; 16(5):e0252222. PubMed ID: 34043697
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
11. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA
J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.
Farzam N; Ramon-Saraf R; Banet-Levi Y; Lerner-Geva L; Ashkenazi S; Kubler-Kielb J; Vinogradov E; Robbins JB; Schneerson R
Vaccine; 2017 Sep; 35(37):4990-4996. PubMed ID: 28797729
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL
Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.
Taylor DN; Trofa AC; Sadoff J; Chu C; Bryla D; Shiloach J; Cohen D; Ashkenazi S; Lerman Y; Egan W
Infect Immun; 1993 Sep; 61(9):3678-87. PubMed ID: 8359890
[TBL] [Abstract][Full Text] [Related]
16. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
Jennison AV; Roberts F; Verma NK
FEMS Immunol Med Microbiol; 2006 Apr; 46(3):444-51. PubMed ID: 16553820
[TBL] [Abstract][Full Text] [Related]
17. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
[TBL] [Abstract][Full Text] [Related]
18. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG
EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589
[TBL] [Abstract][Full Text] [Related]
19.
Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
[No Abstract] [Full Text] [Related]
20. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
Ranallo RT; Thakkar S; Chen Q; Venkatesan MM
Vaccine; 2007 Mar; 25(12):2269-78. PubMed ID: 17229494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
